OPEN-LABEL, SEQUENTIAL-DOSE ESCALATION/DE-ESCALATION TRIAL TESTING MT1002 IN PATIENTS UNDERGOING PCI DUE TO ACUTE CORONARY SYNDROME WITH NSTEMI

Registry ID

MT1002-II-C01

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

SHAANXI MICOT TECHNOLOGY CO. LTD

Start date

2023-03-31

Last update

2021-09-15

Conditions

• ACUTE CORONARY SYNDROME

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF EARLY IN HOSPITAL INITIATION OF INCLISIRAN TREATMENT IN PATIENTS WITH ACUTE CORONARY SYNDROMES: VICTORION - RIDES
• A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS): THE DAL-302 (DAL-GENE-2) TRIAL
• A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS): THE DAL-GENE TRIAL
• A PHASE IB STUDY OF DUVALUMAB (MEDI-4736) WITH OR WITHOUT TREMELIMUMAB IN PATIENTS WITH ADVANCED INCURABLE SOLID MALIGNANCIES RECEIVING STANDARD CHEMOTHERAPY REGIMENS
• A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO COMPARE THE EFFECT OF TREATMENT ON PLAQUE BURDEN AS DETERMINED BY IVUS AND TO EVALUATE THE EFFICACY, PK, SAFETY, AND TOLERABILITY OF MDCO-216 GIVEN AS MULTIPLE WEEKLY INFUSIONS IN SUBJECTS WITH A RECENT ACUTE CORONARY SYNDROME

View on source registry